Bicara Therapeutics BCAX Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodValueNewIssues.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's issuance of common stock in connection with the spin-off and reclassification of net parent investment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's issuance of common stock in connection with the spin-off and reclassification of net parent investment?
- Bicara Therapeutics (BCAX) reported issuance of common stock in connection with the spin-off and reclassification of net parent investment of $161.76M in Q1 2026.
- How has Bicara Therapeutics's issuance of common stock in connection with the spin-off and reclassification of net parent investment changed year-over-year?
- Bicara Therapeutics's issuance of common stock in connection with the spin-off and reclassification of net parent investment increased by 2093.5% year-over-year, from $7.37M to $161.76M.
- What does issuance of common stock in connection with the spin-off and reclassification of net parent investment mean?
- The total dollar value of new common stock issued by the company during the period, typically excluding exercises of existing options. This represents a primary source of external financing used to fund operations, research, or strategic initiatives. It reflects the company's ability to access capital markets to support its growth objectives.